Melodiol Global Health (ASX:ME1) 1-Year Share Buyback Ratio : 0.00% (As of Dec. 2023 )

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Melodiol Global Health's current 1-Year Share Buyback Ratio was 0.00%.

ASX:ME1's 1-Year Share Buyback Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -1.8
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Competitive Comparison of Melodiol Global Health's 1-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's 1-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Melodiol Global Health 1-Year Share Buyback Ratio Calculation

Melodiol Global Health's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2023 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2022 )	-	Shares Outstanding (EOP) (Dec. 2023 ))	/	Shares Outstanding (EOP) (Dec. 2022 )
	=	(3.060	-	7.881)	/	3.060
	=	-157.5%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Melodiol Global Health (ASX:ME1) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Melodiol Global Health 1-Year Share Buyback Ratio Related Terms

Melodiol Global Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.melodiolglobalhealth.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: USA-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health Headlines

No Headlines